Search results
Results from the WOW.Com Content Network
In the documentary, filmmaker Liz Canner takes a job editing erotic movies for a drug trial for a pharmaceutical company called Vivus. Her employer is developing what they hope will be the first Viagra drug for women that wins FDA approval to treat a new disease: female sexual dysfunction (FSD). Liz gains permission to film the company's work ...
Sofosbuvir/velpatasvir, sold under the brand name Epclusa among others, is a fixed-dose combination medication for the treatment of hepatitis C in adults. [ 2 ] [ 5 ] [ 6 ] [ 7 ] It combines sofosbuvir and velpatasvir .
The U.S. Food and Drug Administration is asking a panel of experts to weigh in on a women's version of the male sexual dysfunction drug Viagra. The FDA is considering Boehringer Ingelheim's drug ...
Viagra usually starts working 30 to 60 minutes after taking it. But simply swallowing the little blue pill won’t automatically make you hard — you still have to be aroused, either through ...
Bremelanotide was first developed by Palatin Technologies, then out-licensed to AMAG Pharmaceuticals Inc. after its approval by the FDA on 21 June 2019. [23] Marked as VyleesiTM, it was primarily designed for both men and women in the form of an intranasal formulation, particularly for treating male erectile dysfunction. [23]
Therefore, there’s no true equivalent of a Viagra-like medication for women on the market, simply because genital function is different between the sexes. Yet women do experience sexual ...
She sold Sprout to Valeant in 2015 after the company won FDA approval for the drug Addyi, the first drug designed to enhance female libido. [13] Prior to founding Sprout, Eckert co-founded Slate Pharmaceuticals in 2007. Slate was focused on men's sexual health with an FDA approved long acting testosterone product, Testopel.
A panel of U.S. Food and Drug Administration experts decided Friday that Boehringer Ingelheim's so-called "female viagra" drug, flibanserin, doesn't provide enough benefit to outweigh the risks.